PTCT
NASDAQPTC Therapeutics Inc.
News · 26 weeks76+10%
2026-01-182026-07-12
Mix3790d
- Insider15(41%)
- SEC Filings9(24%)
- Earnings5(14%)
- Other5(14%)
- Analyst3(8%)
Latest news
25 items- INSIDERCHIEF FINANCIAL OFFICER Gravier Pierre sold $280,743 worth of shares (3,494 units at $80.35), decreasing direct ownership by 4% to 83,986 units (SEC Form 4) to satisfy withholding obligation4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- PRPTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026WARREN, N.J., July 16, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the company will host a webcast conference call to report its second quarter 2026 financial results and provide an update on the company's business and outlook on Thursday, July 30, 2026, at 4:30 p.m. ET. To access the live webcast, please visit the "Events & Presentations" page within the Investors section of the PTC website. A replay of the webcast will be available on the PTC website for 30 days following the event. To participate via phone, please register in advance here to receive dial-in details.About PTC Therapeutics, I
- INSIDERCHIEF TECHNICAL OPS OFFICER Almstead Neil Gregory exercised 2,464 shares at a strike of $46.54 and sold $222,376 worth of shares (2,464 units at $90.25) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERDirector Smith Mary L. exercised 15,834 shares at a strike of $42.95 and sold $1,425,060 worth of shares (15,834 units at $90.00) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERCHIEF TECHNICAL OPS OFFICER Almstead Neil Gregory exercised 46,774 shares at a strike of $38.86 and sold $4,093,482 worth of shares (46,774 units at $87.52) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDEREXEC. VP AND CLO Boulding Mark Elliott sold $432,118 worth of shares (5,079 units at $85.08) as part of a pre-agreed trading plan and exercised 5,079 shares at a strike of $43.36 (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERCHIEF TECHNICAL OPS OFFICER Almstead Neil Gregory exercised 8,130 shares at a strike of $38.10 and sold $693,151 worth of shares (8,130 units at $85.26) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERCHIEF TECHNICAL OPS OFFICER Almstead Neil Gregory exercised 26,283 shares at a strike of $38.11 and sold $2,254,463 worth of shares (26,283 units at $85.78) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERCHIEF TECHNICAL OPS OFFICER Almstead Neil Gregory exercised 23,749 shares at a strike of $25.69 and sold $1,921,378 worth of shares (23,749 units at $80.90) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDEREXEC. VP AND CLO Boulding Mark Elliott exercised 10,522 shares at a strike of $46.54 and sold $822,868 worth of shares (10,462 units at $78.65) as part of a pre-agreed trading plan, increasing direct ownership by 0.06% to 105,272 units (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERSVP, CHIEF ACCOUNTING OFFICER Utter Christine Marie exercised 19,686 shares at a strike of $25.69 and sold $1,487,474 worth of shares (19,686 units at $75.56) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- SECPTC Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)
- PRPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WARREN, N.J., June 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that on June 11, 2026, the company approved non-statutory stock options to purchase an aggregate of 10,050 shares of its common stock and 11,870 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 18 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on June 11, 2026, and are being made as an inducement material to each employee's acceptance of employment with the company
- SECPTC Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)
- PRPTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes– Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 convertible notes prior to or at maturity –– Offering made at 0% interest with conversion price of $107.48, a 40% premium over the closing price on June 15, 2026 –WARREN, N.J., June 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced the pricing of $500.0 million aggregate principal amount of 0% Convertible Senior Notes due 2031 (the "Notes") in a private placement (the "Offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). PTC also granted the initial purchasers an option to purchase, within the 13
- PRPTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes– Proceeds to be used to repurchase or repay 2026 convertible notes prior to or at maturity – – Offering to include buyback of common stock –WARREN, N.J., June 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2031 (the "Notes") in a private placement (the "Offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). PTC intends to grant the initial purchasers an option to purchase, within a 13-day period beginning on, and including, the date o
- INSIDERCHIEF BUSINESS OFFICER Pauwels Eric sold $1,595,775 worth of shares (21,277 units at $75.00) as part of a pre-agreed trading plan and exercised 17,566 shares at a strike of $18.01, decreasing direct ownership by 5% to 73,411 units (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- SECPTC Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)
- ANALYSTPTC Therapeutics upgraded by Citigroup with a new price targetCitigroup upgraded PTC Therapeutics from Neutral to Buy and set a new price target of $108.00
- SECPTC Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)
- ANALYSTPTC Therapeutics upgraded by Jefferies with a new price targetJefferies upgraded PTC Therapeutics from Hold to Buy and set a new price target of $85.00
- INSIDEREXEC. VP AND CLO Boulding Mark Elliott sold $202,958 worth of shares (2,812 units at $72.18) as part of a pre-agreed trading plan and exercised 2,812 shares at a strike of $25.69 (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Klein Matthew B. sold $917,154 worth of shares (12,572 units at $72.95) and was granted 12,500 shares, decreasing direct ownership by 0.02% to 393,998 units (SEC Form 4) to satisfy tax liability4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by PTC Therapeutics Inc.SCHEDULE 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)
- INSIDEREXEC. VP AND CLO Boulding Mark Elliott exercised 3,540 shares at a strike of $46.54 and sold $279,570 worth of shares (3,540 units at $78.97) as part of a pre-agreed trading plan (SEC Form 4)4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
PTCT FAQ
7 questionsWhat does PTC Therapeutics Inc. do?
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States...Where does PTCT stock trade?
PTC Therapeutics Inc. (PTCT) is listed on NASDAQ.What sector and industry is PTCT in?
PTC Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did PTC Therapeutics Inc. go public?
PTC Therapeutics Inc. (PTCT) completed its IPO in 2013.What are analysts saying about PTCT?
PTC Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy on 2026-06-09.What companies are similar to PTCT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PTCT side-by-side with any of them on Quantisnow.How can I track PTCT on Quantisnow?
Quantisnow aggregates PTC Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PTCT to receive live email and push alerts on every new disclosure.